| II-01 Nina Scherer A population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions Wednesday 15:10-16:30 |
| II-02 Emilie Schindler The minimal continuous-time Markov pharmacometric model Wednesday 15:10-16:30 |
| II-03 Rik Schoemaker nlmixr: an open-source package for pharmacometric modelling in R Wednesday 15:10-16:30 |
| II-04 Johannes Schropp Target-mediated drug disposition model for a bispecific antibody: development of full model and quasi-equilibrium like approximation Wednesday 15:10-16:30 |
| II-05 Pascal Schulthess Frequency-domain response analysis for quantitative systems pharmacology models Wednesday 15:10-16:30 |
| II-06 Bernard Sebastien Pharmacokinetic/Pharmacodynamic Modelling of Recurrent Adverse Events as Function of Drug Concentration and Time Wednesday 15:10-16:30 |
| II-07 Malte Selch Larsen Using repeated-time-to-event modelling and simulation of spontaneous bleeding events in the F8 KO rat model for informed decision making of study design Wednesday 15:10-16:30 |
| II-08 Marina Senek Population pharmacokinetic model for levodopa/carbidopa microtablets in Parkinson’s disease patients and healthy subjects Wednesday 15:10-16:30 |
| II-09 Jennifer Sheng Joint modeling of time-varying exposure data and progression-free survival in elotuzumab-treated patients with relapsed/refractory multiple myeloma Wednesday 15:10-16:30 |
| II-10 Satoshi Shoji Slow drug-target complex kinetics and first dose overestimation of free target suppression in target-mediated drug disposition (TMDD) approximation models: An evaluation for tanezumab a NGF antibody for treatment of pain Wednesday 15:10-16:30 |
| II-11 Mahendra Shukla Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect Wednesday 15:10-16:30 |
| II-13 Sarah Siederer Model Based Extrapolation Approach Driving a Streamlined Clinical Development Plan for Inhaled Oxytocin Wednesday 15:10-16:30 |
| II-14 Giovanni Smania The role of modelling and simulation in the paediatric investigation plan of a xanthine oxidase inhibitor for tumor lysis syndrome prevention Wednesday 15:10-16:30 |
| II-15 Konstantina Soulele Population pharmacokinetic analysis of inhaled budesonide in asthma patients Wednesday 15:10-16:30 |
| II-17 Sabine Stuebler Towards a systems biology model for inflammatory bowel disease Wednesday 15:10-16:30 |
| II-19 Waroonrat Sukarnjanaset Performance of FOCEI vs SAEM in simple population pharmacokinetic analysis of rich, medium and sparse data. Wednesday 15:10-16:30 |
| II-20 Monika Sundqvist Preclinical pharmacokinetic-pharmacodynamic modelling to guide first-time-in-human studies with the anti-miR-103/107, RG-125 (AZD4076) Wednesday 15:10-16:30 |
| II-21 Ajit Suri Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies Wednesday 15:10-16:30 |
| II-22 Elin Svensson Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis Wednesday 15:10-16:30 |
| II-23 Lénaïg Tanneau Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209 Wednesday 15:10-16:30 |
| II-24 Joel Tarning Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis Wednesday 15:10-16:30 |
| II-25 Adrien Tessier Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats Wednesday 15:10-16:30 |
| II-26 Donato Teutonico Development of a PBPK model to describe late colonic absorption after oral administration Wednesday 15:10-16:30 |
| II-27 Tjokosela Tikiso Population Pharmacokinetics of Abacavir in HIV-infected African children Wednesday 15:10-16:30 |
| II-28 Valentina Topic Vucenovic Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease Wednesday 15:10-16:30 |
| II-29 Elena Tosca A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens Wednesday 15:10-16:30 |
| II-30 Mirjam Trame Translational in-vitro in-vivo model to correlate HIPS derived cardiomyocyte contractility assay and in-vivo dog telemetry based dPdtmax measurements Wednesday 15:10-16:30 |
| II-31 Alexios Tsiligiannis Optimization of a paediatric FDC tablet and dosing regimen for the first line treatment of tuberculosis. Wednesday 15:10-16:30 |
| II-32 Periklis Tsiros Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam Wednesday 15:10-16:30 |
| II-33 Eirini Tsotsou Population pharmacokinetics of gentamycin in hospitalized ICU patients Wednesday 15:10-16:30 |
| II-34 Denise Feick Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone Wednesday 15:10-16:30 |
| II-35 Zofia Tylutki Simulation of pharmacokinetics of amitriptyline and nortriptyline and their common effect on human cardiac electrophysiology in healthy population Wednesday 15:10-16:30 |
| II-36 Sebastian Ueckert Solving linear ODEs using Krylov subspace projection methods Wednesday 15:10-16:30 |
| II-37 Sami Ullah Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis Wednesday 15:10-16:30 |
| II-38 Moreno Ursino dfpk: an R package for a practical implementation of PK measurements in dose-finding studies Wednesday 15:10-16:30 |
| II-39 Pavan Vaddady A Comprehensive Model-Based Meta-Analysis (MBMA) of Diabetes Studies in Type 2 Diabetes Mellitus Patients to Quantify the Relationship between HbA1c and Fasting Plasma Glucose Wednesday 15:10-16:30 |
| II-40 Elodie Valade Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers Wednesday 15:10-16:30 |
| II-41 Tamara van Donge Impact of rise in anti-drug antibodies on the pharmacokinetics of the monoclonal antibody adalimumab Wednesday 15:10-16:30 |
| II-42 Michiel Van Esdonk Quantifying the growth hormone lowering effect of BIM23B065 after a GH stimulation test Wednesday 15:10-16:30 |
| II-43 Eline van Maanen A systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation Wednesday 15:10-16:30 |
| II-44 Erno van Schaick CHF5993 a triple combination therapy for COPD patients: population PK modelling of formoterol following pMDI inhalation Wednesday 15:10-16:30 |
| II-45 Rob van Wijk A parent-metabolite pharmacokinetic model of paracetamol in zebrafish Wednesday 15:10-16:30 |
| II-46 Marc Vandemeulebroecke Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development Wednesday 15:10-16:30 |
| II-47 Swantje Völler Normalisation weight in a covariate function affects the relative standard error of clearance: an example with paediatric data Wednesday 15:10-16:30 |
| II-48 Veronika Voronova Evaluation of immediate release exenatide effects on gastric motility and intestinal glucose absorption using a systems pharmacology model Wednesday 15:10-16:30 |
| II-49 Janet Wade Population PK analysis of Sym004 and the influence of variations in base model structure on covariate model building Wednesday 15:10-16:30 |
| II-50 Thanaporn Wattanakul Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria Wednesday 15:10-16:30 |
| II-51 Sebastian Weber Bayesian Pharmacokinetic Extrapolation from Dense Adult to Sparse Pediatric Data Wednesday 15:10-16:30 |
| II-52 Janak Wedagedera Statistical Power Analysis to Detect Drug-Drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modelling and the Simcyp R Package Wednesday 15:10-16:30 |
| II-53 Gustaf Wellhagen Impact of genotype assumption in a semi-mechanistic PK model of metformin Wednesday 15:10-16:30 |
| II-54 Thomas Wendl The Open Systems Pharmacology Suite (PK-Sim® & MoBi®): An open source solution for whole-body physiologically based pharmacokinetics and -dynamics Wednesday 15:10-16:30 |
| II-55 Sebastian Wicha The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate. Wednesday 15:10-16:30 |
| II-56 Mélanie Wilbaux Effects of Formula Milk on Weight Changes in Healthy Term and Preterm Neonates Wednesday 15:10-16:30 |
| II-57 Francis Williams Ojara Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer Wednesday 15:10-16:30 |
| II-58 Jan-Georg Wojtyniak Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2 Wednesday 15:10-16:30 |
| II-60 Gudrun Wuerthwein Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL Wednesday 15:10-16:30 |
| II-61 Rujia Xie Population pharmacokinetics of PF-04447943 in healthy volunteers (HV), adult patients with Alzheimer's disease (AD) and patients with Sickle Cell Disease (SCD) Wednesday 15:10-16:30 |
| II-62 Joao Paulo Ximenez Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients Wednesday 15:10-16:30 |
| II-63 Christine Xu Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis Wednesday 15:10-16:30 |
| II-64 Dong-Seok Yim Discrepancy between in vitro potency and in vivo efficacy in human - Implications in PK-PD modeling Wednesday 15:10-16:30 |
| II-65 Anyue Yin Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis Wednesday 15:10-16:30 |
| II-66 Gunnar Yngman Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling Wednesday 15:10-16:30 |
| II-67 Zakaria Zaril A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection. Wednesday 15:10-16:30 |
| II-68 Chiara Zecchin Quantitative modelling to assess target engagement and pharmacology in early clinical development of an anti-OSM humanised mAb Wednesday 15:10-16:30 |
| II-69 Meng Zhaoling Exposure/Response modeling for sarilumab dose regimens benefit/risk assessment Wednesday 15:10-16:30 |
| II-70 Jochen Zisowsky Simulation Study on a Method for PK-QT Analyses When Several Active Compounds or Metabolites Are Present Wednesday 15:10-16:30 |
